Cerity Partners LLC Invests $220,000 in Qiagen (NYSE:QGEN)

Cerity Partners LLC bought a new position in shares of Qiagen (NYSE:QGEN) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 5,070 shares of the company’s stock, valued at approximately $220,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Briaud Financial Planning Inc acquired a new stake in shares of Qiagen during the third quarter worth $31,000. Toronto Dominion Bank acquired a new stake in shares of Qiagen during the third quarter worth $41,000. Blue Trust Inc. raised its position in shares of Qiagen by 253.9% during the fourth quarter. Blue Trust Inc. now owns 3,974 shares of the company’s stock worth $161,000 after purchasing an additional 2,851 shares during the period. Signaturefd LLC raised its position in shares of Qiagen by 9.0% during the third quarter. Signaturefd LLC now owns 4,686 shares of the company’s stock worth $190,000 after purchasing an additional 385 shares during the period. Finally, First Trust Direct Indexing L.P. acquired a new stake in shares of Qiagen during the third quarter worth $253,000. 70.00% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on QGEN shares. Morgan Stanley upgraded Qiagen from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $49.48 to $51.00 in a report on Friday, February 16th. JPMorgan Chase & Co. lifted their price target on Qiagen from $50.00 to $52.00 and gave the company an “overweight” rating in a report on Thursday, February 8th. Finally, Citigroup lowered their price target on Qiagen from $61.86 to $60.00 and set a “buy” rating on the stock in a report on Thursday, February 8th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $51.69.

Qiagen Stock Performance

Shares of NYSE QGEN opened at $42.32 on Tuesday. The business’s 50-day moving average price is $42.57 and its two-hundred day moving average price is $42.69. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.99 and a quick ratio of 1.62. Qiagen has a one year low of $34.74 and a one year high of $47.70. The company has a market capitalization of $9.66 billion, a P/E ratio of 28.03, a price-to-earnings-growth ratio of 3.51 and a beta of 0.41.

Qiagen (NYSE:QGEN) last issued its earnings results on Tuesday, February 6th. The company reported $0.55 EPS for the quarter, meeting analysts’ consensus estimates of $0.55. Qiagen had a return on equity of 12.99% and a net margin of 17.37%. The firm had revenue of $509.00 million for the quarter, compared to the consensus estimate of $500.77 million. During the same quarter in the previous year, the company posted $0.53 earnings per share. Analysts anticipate that Qiagen will post 2.09 earnings per share for the current fiscal year.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.